Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
837.57
-5.00 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Eli Lilly (LLY): Buy, Sell, or Hold Post Q4 Earnings?
February 21, 2025
Over the past six months, Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the S&P 500 has climbed by 8.9%. This might have...
Via
StockStory
Topics
Stocks
Exposures
US Equities
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
February 21, 2025
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.
Via
Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
February 20, 2025
Tariffs could have big impact on earnings in 2025.
Via
Talk Markets
Topics
Stocks / Equities
Eli Lilly's Options Frenzy: What You Need to Know
February 20, 2025
Via
Benzinga
Biogen Stock Is Mutating Into a Value Play
February 20, 2025
Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X
Via
MarketBeat
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
February 14, 2025
Via
Benzinga
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
February 13, 2025
Via
The Motley Fool
Behind the Scenes of Eli Lilly's Latest Options Trends
February 12, 2025
Via
Benzinga
Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News
February 19, 2025
The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.
Via
The Motley Fool
Digging Into What Hershey and Eli Lilly Told Investors
February 19, 2025
Via
The Motley Fool
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
February 18, 2025
After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.
Via
MarketBeat
3 Hot Stocks That Have Already Doubled in 2025
February 18, 2025
It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.
Via
The Motley Fool
Hims & Hers Stock Is On Fire, But Is It a Bubble?
February 18, 2025
The stock isn't as expensive as you might think.
Via
The Motley Fool
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
February 18, 2025
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Via
Benzinga
Exposures
Product Safety
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
February 18, 2025
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent...
Via
Benzinga
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
February 17, 2025
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
Via
Benzinga
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
February 17, 2025
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?
Via
MarketBeat
3 Stocks That Could Trounce the Market in 2025
February 17, 2025
Via
The Motley Fool
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
February 15, 2025
Via
The Motley Fool
MarketBeat Week in Review – 02/10 - 02/14
February 15, 2025
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in
Via
MarketBeat
Topics
Credit Cards
Economy
Government
Exposures
Interest Rates
Political
Tariff
Top Stock Reports For Apple, Eli Lilly & Shopify
February 14, 2025
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co., and Shopify Inc., as well as a micro-cap stock ImmuCell Corp.
Via
Talk Markets
Topics
Stocks / Equities
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
February 13, 2025
Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
Via
Benzinga
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
February 12, 2025
GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.
Via
MarketBeat
Exposures
Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
February 11, 2025
Via
Benzinga
Healthcare And Biotech Playbook As Disruption Gathers Force
February 10, 2025
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
February 10, 2025
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
Via
Benzinga
5 ETFs That Beat Market Turmoil With Gains Last Week
February 10, 2025
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs.
Via
Benzinga
Topics
ETFs
Economy
Exposures
Interest Rates
These Stocks Missed on Earnings, But Will Rebound Next Quarter
February 10, 2025
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year
Via
MarketBeat
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
February 10, 2025
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.